Ifølge Clinical Trial Gov så er der "Estimated Study Start Date: September 28, 2018" på studiet med titlen "A phase 3, randomized, double-blind, placebo- and active-controlled, parallel-arm trial to assess the efficacy, safety, and pharmacokinetics of dasiglucagon relative to placebo and GlucaGen® when administered as a rescue therapy for severe hypoglycemia in children with T1DM treated with insulin".


Vi har spørgsmål til netop dette forsøg i vor seneste Q&A med Zealand Pharma.
http://www.proinvestor.com/ir/q-and-a/dk
http://www.proinvestor.com/ir/q-and-a/dk


Hej ElliotSpitzer, Har du et bud på tidshorisonten på studiet? På forhånd tak. Mvh Bent


Estimated Primary Completion Date : July 1, 2019
Estimated Study Completion Date : August 1, 2019
Estimated Study Completion Date : August 1, 2019


Nu kom der så også meddelse om det - Kl. 14:53:11 CET
Company announcement - No. 24 / 2018
Zealand Pharma has initiated the Phase 3 trial with dasiglucagon for treatment of severe hypoglycemia in children
Company announcement - No. 24 / 2018
Zealand Pharma has initiated the Phase 3 trial with dasiglucagon for treatment of severe hypoglycemia in children